Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Operating Income: 2009-2025

Historic Operating Income for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $388.5 million.

  • UNITED THERAPEUTICS's Operating Income rose 13.23% to $388.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 16.73%. This contributed to the annual value of $1.4 billion for FY2024, which is 16.21% up from last year.
  • UNITED THERAPEUTICS's Operating Income amounted to $388.5 million in Q3 2025, which was up 6.58% from $364.5 million recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Operating Income ranged from a high of $388.5 million in Q3 2025 and a low of -$64.8 million during Q1 2021.
  • Its 3-year average for Operating Income is $336.2 million, with a median of $343.1 million in 2024.
  • As far as peak fluctuations go, UNITED THERAPEUTICS's Operating Income slumped by 138.87% in 2021, and later skyrocketed by 544.44% in 2022.
  • Quarterly analysis of 5 years shows UNITED THERAPEUTICS's Operating Income stood at $169.8 million in 2021, then climbed by 3.42% to $175.6 million in 2022, then spiked by 48.12% to $260.1 million in 2023, then surged by 37.52% to $357.7 million in 2024, then increased by 13.23% to $388.5 million in 2025.
  • Its Operating Income stands at $388.5 million for Q3 2025, versus $364.5 million for Q2 2025 and $382.8 million for Q1 2025.